Dan La Caze

Dan La Caze is the current Chief Business Officer at Elegen. Prior to this, they served as Executive Director of Corporate Development at Berkeley Lights, Inc. from January 2017 to September 2019. From June 2015 to January 2017, they were in Business Development at Natera + Consulting.

Gravid Therapies, Inc. was their previous company before CardioDx, where they served as Head of Business Development from June 2012 to May 2015. Prior to that, they were with Genoptix from January 2009 to December 2012 as Sr. Director of Corporate Development.

Invitrogen was their first Manager role in Corporate Development from January 2004 to December 2005. From July 2007 to September 2009, they were Associate Director of Business Development before being promoted to Manager of Business Development, a role they held from January 2001 to December 2004.

Dan La Caze began their professional journey as an Associate in Equity Research - Biotechnology at Roth Capital Partners from January 2000 to December 2001.

Dan La Caze's educational career includes completing an MBA at the London Business School and a MS/BS in Molecular & Structural Biology at UC San Diego.

Dan La Caze reports to Matt Hill, Founder & CEO. Dan La Caze works with Marc A. Unger - Chief Scientific Officer, Jodie Bowen - Corporate Controller, and Mark Lasinski - SVP, Sales.